{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:43:24Z","timestamp":1788227004546,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the therapeutic effect of TAC\u2010302, a cyclohexenoic fatty alcohol derivative, on bladder denervation\u2010related storage and voiding dysfunctions in rats with bladder outlet obstruction (BOO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BOO was achieved by partial ligature of the proximal urethra in female rats. Two weeks later, BOO rats were divided into two groups and treated orally with vehicle or 10\u2009mg\/kg TAC\u2010302 twice a day for 4 weeks. Urodynamic and immunohistochemical evaluation of the bladder muscle layer was performed. In another study, the BOO rats were treated with intravenous tamsulosin at cystometry. The detrusor contractility in each group was evaluated using the modified Shafer's nomogram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two weeks after BOO, the rats showed significant increases in non\u2010voiding contraction (NVCs) and residual urine volume (RUV) compared to the sham group. Moreover, 6 weeks after BOO, BOO vehicle rats showed significant increases in NVCs and RUV and decreases in detrusor contractility and in the nerve fiber density in the urinary bladder compared to the sham group. BOO\u2010induced denervation of the urinary bladder was partially improved by oral treatment with TAC\u2010302. Oral treatment with TAC\u2010302 significantly reduced the amplitude and frequency of NVCs (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and increased detrusor contractility and tended to reduce RUV compared with the BOO vehicle group. In contrast, the intravenous administration of tamsulosin significantly reduced the frequency of NVCs, but not RUV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TAC\u2010302 improved storage and voiding dysfunctions by improving bladder denervation and detrusor underactivity even when the treatment was started after storage and voiding dysfunctions had already occurred.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.23571","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T19:44:06Z","timestamp":1523389446000},"page":"2106-2113","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic effect of TAC\u2010302, a cyclohexenoic fatty alcohol derivative, on bladder denervation\u2010related storage and voiding dysfunctions in rats"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-2387","authenticated-orcid":false,"given":"Shohei","family":"Yoshida","sequence":"first","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Noma","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Clinical Development II Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsukihara","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Orimoto","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hakozaki","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Taiho Pharmaceutical Co. Ltd. Drug Discovery and Development II Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_6_3_1","first-page":"S3","article-title":"Pathophysiology of lower urinary tract symptoms in the aging male population","volume":"7","author":"Lepor H","year":"2005","journal-title":"Rev Urol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12652"},{"key":"e_1_2_6_5_1","first-page":"1","article-title":"TAC\u2010302 promotes neurite outgrowth of isolated peripheral neurons and prevents bladder denervation related bladder dysfunctions following bladder outlet obstruction in rats","volume":"26","author":"Yoshida S","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)03007-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90985-K"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/51201439"},{"key":"e_1_2_6_9_1","unstructured":"KokubunS ShishidoK TakahashiN et al. Neuron protection agent TAC\u2010302 prevents bladder denervation and dysfunction following partial bladder obstruction in rats. Poster presented at ICS\u2010IUGA annual meeting; August 23\u201027 2010; Toronto Canada."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.2006.00393.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.06.054"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1987.tb05033.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67951-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44930-5"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43675-5"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67204-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)56918-9"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1992.tb15791.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.04.101"},{"key":"e_1_2_6_20_1","first-page":"1508","article-title":"Influence of bladder outlet obstruction and detrusor contractility on residual urine in patients with benign prostatic hyperplasia","volume":"116","author":"Zhang P","year":"2003","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35867-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67241-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2011.157"},{"key":"e_1_2_6_24_1","first-page":"523","volume-title":"Urine Flow Rates","author":"Terry NL","year":"1983"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1757-5672.2011.00096.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390220074024"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2006.00917.x"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23571","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.23571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T02:25:19Z","timestamp":1694917519000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.23571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/nau.23571"],"URL":"https:\/\/doi.org\/10.1002\/nau.23571","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"2018-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}